Cargando…

Inducing Dose Sparing with Inactivated Polio Virus Formulated in Adjuvant CAF01

The development of new low cost inactivated polio virus based vaccines (IPV) is a high priority, and will be required to eradicate polio. In addition, such a vaccine constitutes the only realistic polio vaccine in the post-eradication era. One way to reduce the cost of a vaccine is to increase immun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dietrich, Jes, Andreasen, Lars Vibe, Andersen, Peter, Agger, Else Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4067388/ https://www.ncbi.nlm.nih.gov/pubmed/24956110 http://dx.doi.org/10.1371/journal.pone.0100879

Ejemplares similares

CAF01 Potentiates Immune Responses and Efficacy of an Inactivated Influenza Vaccine in Ferrets
por: Martel, Cyril Jean-Marie, et al.
Publicado: (2011)

Cationic Liposomes Formulated with Synthetic Mycobacterial Cordfactor (CAF01): A Versatile Adjuvant for Vaccines with Different Immunological Requirements
por: Agger, Else Marie, et al.
Publicado: (2008)

Syringe Free Vaccination with CAF01 Adjuvated Ag85B-ESAT-6 in Bioneedles Provides Strong and Prolonged Protection Against Tuberculosis
por: Christensen, Dennis, et al.
Publicado: (2010)

A Novel Liposome-Based Adjuvant CAF01 for Induction of CD8(+) Cytotoxic T-Lymphocytes (CTL) to HIV-1 Minimal CTL Peptides in HLA-A*0201 Transgenic Mice
por: Gram, Gregers Jacob, et al.
Publicado: (2009)

Subunit vaccine H56/CAF01 induces a population of circulating CD4 T cells that traffic into the Mycobacterium tuberculosis-infected lung
por: Woodworth, Joshua S., et al.
Publicado: (2016)

Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma
por: Mørk, Sofie Kirial, et al.
Publicado: (2022)

Intradermal Administration of Fractional Doses of Inactivated Poliovirus Vaccine: A Dose-Sparing Option for Polio Immunization
por: Okayasu, Hiromasa, et al.
Publicado: (2017)

Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial
por: Rivera, Luis, et al.
Publicado: (2017)

Broadening of the T-Cell Repertoire to HIV-1 Gag p24 by Vaccination of HLA-A2/DR Transgenic Mice with Overlapping Peptides in the CAF05 Adjuvant
por: Korsholm, Karen S., et al.
Publicado: (2013)

Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication
por: Kumar, Prashant, et al.
Publicado: (2022)

Analysis of the dose-sparing effect of adjuvanted Sabin-inactivated poliovirus vaccine (sIPV)
por: Li, Zhuofan, et al.
Publicado: (2018)

Influenza NG-34 T cell conserved epitope adjuvanted with CAF01 as a possible influenza vaccine candidate
por: Sisteré-Oró, Marta, et al.
Publicado: (2020)

Prime-Pull Immunization with a Bivalent M-Protein and Spy-CEP Peptide Vaccine Adjuvanted with CAF®01 Liposomes Induces Both Mucosal and Peripheral Protection from covR/S Mutant Streptococcus pyogenes
por: Ozberk, Victoria, et al.
Publicado: (2021)

Seasonal Influenza Split Vaccines Confer Partial Cross-Protection against Heterologous Influenza Virus in Ferrets When Combined with the CAF01 Adjuvant
por: Christensen, Dennis, et al.
Publicado: (2018)

Characterization of the Antigen-Specific CD4(+) T Cell Response Induced by Prime-Boost Strategies with CAF01 and CpG Adjuvants Administered by the Intranasal and Subcutaneous Routes
por: Ciabattini, Annalisa, et al.
Publicado: (2015)

Inactivated Polio Vaccine: Its proposed role in the final stages of polio eradication
por: Davis, Robert, et al.
Publicado: (2013)

Advax-CpG Adjuvant Provides Antigen Dose-Sparing and Enhanced Immunogenicity for Inactivated Poliomyelitis Virus Vaccines
por: Honda-Okubo, Yoshikazu, et al.
Publicado: (2021)

CAF08 adjuvant enables single dose protection against respiratory syncytial virus infection in murine newborns
por: van Haren, Simon D., et al.
Publicado: (2022)

Impact of polio vaccines (oral polio vaccine - OPV or inactivated polio vaccine - IPV) on rotavirus vaccine-associated intussusception
por: Martini Rodrigues, Camila Cristina, et al.
Publicado: (2022)

Psoriasis Sparing the Polio-Affected Limb: Is It Merely the Koebner Phenomenon?
por: Ravikumar, BC, et al.
Publicado: (2014)

Spatial Analyses of Oral Polio Vaccine Transmission in an Community Vaccinated With Inactivated Polio Vaccine
por: Jarvis, Christopher I, et al.
Publicado: (2018)

First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12 months and 5 years of age
por: Lindgren, Line M., et al.
Publicado: (2017)

Simultaneous Subcutaneous and Intranasal Administration of a CAF01-Adjuvanted Chlamydia Vaccine Elicits Elevated IgA and Protective Th1/Th17 Responses in the Genital Tract
por: Wern, Jeanette Erbo, et al.
Publicado: (2017)

Adsorption of protein antigen to the cationic liposome adjuvant CAF®01 is required for induction of Th1 and Th17 responses but not for antibody induction
por: Wørzner, Katharina, et al.
Publicado: (2021)

Development of Thermostable Lyophilized Inactivated Polio Vaccine
por: Kraan, Heleen, et al.
Publicado: (2014)

Next Generation Inactivated Polio Vaccine Manufacturing to Support Post Polio-Eradication Biosafety Goals
por: Thomassen, Yvonne E., et al.
Publicado: (2013)

Therapeutic Vaccination with Cationic Liposomes Formulated with Dioctadecyldimethylammonium and Trehalose Dibehenate (CAF01) and Peptide P10 Is Protective in Mice Infected with Paracoccidioides brasiliensis
por: de Araújo, Marcelo Valdemir, et al.
Publicado: (2020)

Impact of Maternal Antibody on the Immunogenicity of Inactivated Polio Vaccine in Infants Immunized With Bivalent Oral Polio Vaccine: Implications for the Polio Eradication Endgame
por: Gaensbauer, James T, et al.
Publicado: (2018)

Targeting the Mincle and TLR3 receptor using the dual agonist cationic adjuvant formulation 9 (CAF09) induces humoral and polyfunctional memory T cell responses in calves
por: Thakur, Aneesh, et al.
Publicado: (2018)

Lessons Learned From Managing the Planning and Implementation of Inactivated Polio Vaccine Introduction in Support of the Polio Endgame
por: Zipursky, Simona, et al.
Publicado: (2017)

Genital Infiltrations of CD4(+) and CD8(+) T Lymphocytes, IgA(+) and IgG(+) Plasma Cells and Intra-Mucosal Lymphoid Follicles Associate With Protection Against Genital Chlamydia trachomatis Infection in Minipigs Intramuscularly Immunized With UV-Inactivated Bacteria Adjuvanted With CAF01
por: Erneholm, Karin, et al.
Publicado: (2019)

Protocol for a systematic review and meta-analysis of fractional dose compared with standard dose inactivated polio vaccination in children
por: Mashunye, Thandiwe Runyararo, et al.
Publicado: (2019)

ESAT-6 (EsxA) and TB10.4 (EsxH) Based Vaccines for Pre- and Post-Exposure Tuberculosis Vaccination
por: Hoang, Truc, et al.
Publicado: (2013)

First in man study: Bcl-Xl_42-CAF(®)09b vaccines in patients with locally advanced prostate cancer
por: Mørk, Sofie Kirial, et al.
Publicado: (2023)

Immune responses following neonatal vaccination with conserved F4 fragment of VtaA proteins from virulent Glaesserella parasuis adjuvanted with CAF®01 or CDA
por: López-Serrano, Sergi, et al.
Publicado: (2023)

Polio inactivated vaccine costs into routine childhood immunization in Brazil
por: Sartori, Ana Marli Christovam, et al.
Publicado: (2015)

Persistence of protective anti-poliovirus antibody levels in 4-year-old children previously primed with Picovax®, a trivalent, aluminium-adjuvanted reduced dose inactivated polio vaccine
por: Sáez-Llorens, Xavier, et al.
Publicado: (2022)

Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax™ delta inulin adjuvant
por: Gordon, David L., et al.
Publicado: (2016)

Introduction of Inactivated Poliovirus Vaccine and Trivalent Oral Polio Vaccine/Bivalent Oral Polio Vaccine Switch in the African Region
por: Tevi-Benissan, Carol, et al.
Publicado: (2017)

Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine
por: Brickley, Elizabeth B, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mu4besevqbnul6bicnbvg1kmlt